Form 4: Travere Therapeutics CLO Sells Shares Under 10b5-1 Plan

Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, sold common stock totaling 2,994 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics, Inc. (TVTX), reported transactions.
• On February 4, 2026, Reed sold 2,485 shares of Common Stock at a weighted average price of $32.07 per share.
• The price range for this transaction was between $31.63 and $32.61.
• On the same date, Reed sold an additional 509 shares of Common Stock at a weighted average price of $32.74 per share.
• The price range for this second transaction was between $32.64 and $32.90.
• These sales were executed pursuant to a Rule 10b5-1(c) written plan adopted on June 16, 2025.
• The sales included shares to cover tax obligations arising from the vesting of restricted stock units.
• Following these transactions, Elizabeth E. Reed beneficially owns 105,211 shares of Travere Therapeutics Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executives managing equity compensation and tax liabilities through a pre-arranged 10b5-1 plan, rather than a signal of management's outlook on the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans, particularly those explicitly stated to cover tax obligations from equity vesting, are a common practice among corporate executives. These pre-arranged plans are designed to allow insiders to sell shares without concerns of trading on material non-public information and are often part of routine personal financial planning.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of outstanding shares, but the impact is generally negligible given the volume and nature of the transaction.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The reported sale by the Chief Legal Officer was executed under a pre-arranged 10b5-1 plan and explicitly included shares sold to cover tax obligations arising from restricted stock unit vesting. This is a common and routine practice for executives and does not typically signal a change in the company's fundamental prospects or warrant a shift in investment recommendation.

Keywords

Travere Therapeutics, TVTX, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Elizabeth E. Reed, Chief Legal Officer